Jim Simons Enlivex Therapeutics Ltd. Transaction History
Renaissance Technologies LLC
- $56.7 Billion
- Q2 2024
A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Renaissance Technologies LLC holds 71,689 shares of ENLV stock, worth $113,985. This represents 0.0% of its overall portfolio holdings.
Number of Shares
71,689
Previous 69,889
2.58%
Holding current value
$113,985
Previous $265,000
61.89%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding ENLV
# of Institutions
22Shares Held
2.1MCall Options Held
16.1KPut Options Held
3.4K-
Armistice Capital, LLC New York, NY1.7MShares$2.7 Million0.03% of portfolio
-
Morgan Stanley New York, NY245KShares$389,3780.0% of portfolio
-
Xtx Topco LTD London, X024.8KShares$39,4630.0% of portfolio
-
Act Capital Management, LLC Wayne, PA15KShares$23,8500.09% of portfolio
-
Goldman Sachs Group Inc New York, NY11.4KShares$18,1720.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $29.3M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...